share_log

Biomerica | 10-K: FY2024 Annual Report

Biomerica | 10-K: FY2024 Annual Report

Biomerica | 10-K：2024财年年报
美股SEC公告 ·  2024/08/28 14:03

Moomoo AI 已提取核心信息

Biomerica reported fiscal year 2024 revenue of $5.4 million, a slight increase from $5.3 million in FY2023, with gross profit improving to $611,000 from $446,000. The company's core non-COVID product sales grew 5% year-over-year, driven by a 22% increase in over-the-counter product sales and 21% growth in contract manufacturing revenue.Operating expenses decreased 9% to $7.0 million, reflecting cost reduction initiatives including lower legal expenses and share-based compensation. The company maintained focus on strategic priorities, investing in sales team expansion while implementing efficiency measures. Net loss improved to $6.0 million from $7.1 million in the prior year.The company faces liquidity challenges with cash declining to $4.2 million from $9.7 million, prompting a 15% workforce reduction in July 2024. Management is actively pursuing strategic alternatives while advancing commercialization of key products including inFoods IBS diagnostic and recently FDA-cleared hp+detect for H. pylori detection.
Biomerica reported fiscal year 2024 revenue of $5.4 million, a slight increase from $5.3 million in FY2023, with gross profit improving to $611,000 from $446,000. The company's core non-COVID product sales grew 5% year-over-year, driven by a 22% increase in over-the-counter product sales and 21% growth in contract manufacturing revenue.Operating expenses decreased 9% to $7.0 million, reflecting cost reduction initiatives including lower legal expenses and share-based compensation. The company maintained focus on strategic priorities, investing in sales team expansion while implementing efficiency measures. Net loss improved to $6.0 million from $7.1 million in the prior year.The company faces liquidity challenges with cash declining to $4.2 million from $9.7 million, prompting a 15% workforce reduction in July 2024. Management is actively pursuing strategic alternatives while advancing commercialization of key products including inFoods IBS diagnostic and recently FDA-cleared hp+detect for H. pylori detection.
Biomerica报告2024财年的营业收入为540万美元，比2023财年的530万美元略有增长，毛利润从446,000美元改善至611,000美元。公司的核心非COVID产品销售同比增长5%，主要受到非处方产品销售增长22%和合同制造营业收入增长21%的推动。营业费用减少9%，至700万美元，反映了包括降低法律费用和基于股份的补偿在内的成本削减措施。公司保持了对战略优先事项的关注，同时投资于销售团队的扩展，并实施效率提升措施。净亏损从前一年的710万美元改善至600万美元。公司面临流动性挑战，现金从970万美元下降至420万美元，这促使在2024年7月减少15%的员工。管理层积极寻求战略替代方案，同时推进关键产品的商业化，包括inFoods IBS诊断和近期获得FDA批准的hp+detect用于检测幽门螺旋杆菌。
Biomerica报告2024财年的营业收入为540万美元，比2023财年的530万美元略有增长，毛利润从446,000美元改善至611,000美元。公司的核心非COVID产品销售同比增长5%，主要受到非处方产品销售增长22%和合同制造营业收入增长21%的推动。营业费用减少9%，至700万美元，反映了包括降低法律费用和基于股份的补偿在内的成本削减措施。公司保持了对战略优先事项的关注，同时投资于销售团队的扩展，并实施效率提升措施。净亏损从前一年的710万美元改善至600万美元。公司面临流动性挑战，现金从970万美元下降至420万美元，这促使在2024年7月减少15%的员工。管理层积极寻求战略替代方案，同时推进关键产品的商业化，包括inFoods IBS诊断和近期获得FDA批准的hp+detect用于检测幽门螺旋杆菌。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Pacific Biosciences of California
    PACB
    -- 1.850
    Avita Medical
    RCEL
    -- 10.570
    PAVmed
    PAVM
    -- 0.7900
    古特拉
    CUTR
    -- 0.481
    Lifeward
    LFWD
    -- 2.185
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    科技巨头财报季如火如荼，英伟达压轴会表现如何？
    星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星 展开
    亚马逊盈利预告：猜测开盘价，获取奖励！